Damora Therapeutics, Inc. quarterly report, Q2 FY2022

Business Context and Reporting Period

The filing identifies the registrant as Galecto, Inc. (Nasdaq: GLTO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting galectin-3 and LOXL2 for fibrotic diseases and cancer. The reporting period ended June 30, 2022, with comparisons to June 30, 2021. The supplied request metadata names Damora Therapeutics, Inc., which does not match the registrant identified in the filing.

The company had no approved products and generated no product revenue. Key programs included GB0139 for idiopathic pulmonary fibrosis, GB2064 for myelofibrosis, and GB1211 for non-small cell lung cancer and liver cirrhosis.

Financial Results and Key Metrics

MetricThree months ended June 30, 2022Three months ended June 30, 2021Six months ended June 30, 2022Six months ended June 30, 2021
Revenue$0$0$0$0
Research and development expense$13.7 million$8.6 million$26.9 million$18.6 million
General and administrative expense$3.4 million$3.6 million$7.1 million$7.2 million
Total operating expenses$17.1 million$12.3 million$34.1 million$25.8 million
Net loss$16.9 million$12.3 million$33.8 million$25.6 million
Net loss per share$0.67$0.49$1.34$1.02
Operating cash flowNot separately providedNot separately provided$(21.6) million$(25.3) million

Gross and operating margins are not meaningful because the company had no revenue. Six-month research and development expense increased 44.7%, primarily from higher clinical trial costs. The company reported an accumulated deficit of $189.9 million at June 30, 2022.

At June 30, 2022, cash and cash equivalents were $29.8 million, current marketable securities were $49.2 million, and non-current marketable securities were $6.9 million, for total cash, cash equivalents and marketable securities of approximately $85.9 million. Current assets were $82.2 million and current liabilities were $7.5 million. Total liabilities were $7.8 million, consisting primarily of accounts payable, accrued expenses and operating lease liabilities; the filing does not disclose outstanding borrowings or traditional debt.

Six-month investing cash flow was $(10.3) million, reflecting $40.7 million of marketable-security purchases partly offset by $30.4 million of proceeds from sales. Financing cash flow was $18,000 from the issuance of common stock under the company’s at-the-market program.

Material Changes Versus the Prior Comparable Period

  • Three-month research and development expense increased $5.1 million, or 58.7%, to $13.7 million. The increase was primarily attributable to clinical trial activity, including GALACTIC-1 and three other Phase 2 trials.
  • Six-month research and development expense increased $8.3 million, or 44.7%, to $26.9 million. Clinical trial-related costs increased $8.1 million, while chemistry, manufacturing and control costs declined $1.3 million.
  • Three-month net loss increased $4.6 million, or 37.3%, to $16.9 million; six-month net loss increased $8.2 million, or 31.9%, to $33.8 million.
  • Operating cash usage improved to $21.6 million from $25.3 million, primarily because of working-capital changes, despite the higher net loss.
  • Cash, cash equivalents and marketable securities declined from approximately $109.2 million at December 31, 2021 to $85.9 million at June 30, 2022.
  • The company sold 80,306 shares under its ATM program during the three and six months ended June 30, 2022, generating approximately $18,000 in net proceeds.
  • Stock-based compensation increased to $2.8 million for the first six months of 2022 from $2.0 million in the prior-year period.

Guidance, Outlook, Risks and Unusual Items

  • Management expects topline results from the GB0139 GALACTIC-1 Phase 2b trial in mid-2023. Target enrollment of 141 patients was completed in the second quarter of 2022.
  • Intermediate results from the GB2064 MYLOX-1 Phase 2a trial were expected in the third quarter of 2022, with topline results expected in the first half of 2023.
  • Topline results from the GB1211 GULLIVER-2 liver-cirrhosis trial were expected in the third quarter of 2022, and topline results from the GALLANT-1 NSCLC trial were expected in mid-2023.
  • Based on its current operating plan, management believed the $85.9 million of cash, cash equivalents and marketable securities at June 30, 2022 would fund operating and capital expenditures into the second half of 2024. This estimate depends on assumptions that may prove inaccurate.
  • The company expects continued operating losses and increasing research and development, general and administrative and capital expenditures. Additional financing will be required, potentially through equity, debt, collaborations or licensing arrangements.
  • Failure to obtain additional capital could require the company to delay, reduce or terminate development programs. Equity financing could dilute existing stockholders, while debt financing could impose restrictive covenants.
  • COVID-19 caused delays and difficulties in clinical-trial initiation and patient recruitment. Further disruptions could delay enrollment, trial completion and planned readouts.
  • The company faces customary biotechnology risks, including clinical and regulatory failure, inability to commercialize candidates, manufacturing and supply constraints, intellectual-property challenges, competition, dependence on third parties and key personnel, and uncertainty regarding future revenue.
  • A $70,000 loss on the sale of marketable securities was recognized during the three and six months ended June 30, 2022. Marketable securities also had $367,000 of aggregate unrealized losses at June 30, 2022.
  • No material changes to commitments, contingencies or risk factors were reported, and the company reported no material legal proceedings.

Important Facts for Investors to Verify

  • Confirm the issuer identity: the filing is for Galecto, Inc., not Damora Therapeutics, Inc.
  • Verify clinical-trial enrollment, timing and subsequent results for GALACTIC-1, MYLOX-1, GULLIVER-2 and GALLANT-1.
  • Assess whether the projected liquidity runway into the second half of 2024 remains valid as trial spending increases.
  • Review the company’s need for future financing, potential dilution and availability under the $50.0 million ATM program and $200.0 million shelf registration.
  • Monitor cash burn, clinical-trial accrual estimates, marketable-security losses and changes in working capital.
  • Evaluate regulatory, safety, efficacy, manufacturing, intellectual-property and commercialization risks for GB0139, GB2064 and GB1211.
  • Consider stock-option dilution: 5.76 million options were outstanding at June 30, 2022, and 5.46 million were vested or expected to vest.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.